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The use of alternative donor transplants is increasing as the transplantation-eligible population ages and
sibling donors are less available. We evaluated the impact of donor source on transplantation outcomes for
adults with acute myeloid leukemia undergoing myeloablative (MA) or reduced-intensity conditioning (RIC)
transplantation. Between January 2000 and December 2010, 414 consecutive adult patients with acute
myeloid leukemia in remission received MA or RIC allogeneic transplantation from either a matched related
donor (n ¼ 187), unrelated donor (n ¼ 76), or umbilical cord blood donor (n ¼ 151) at the University of
Minnesota or Hôpital St. Louis in Paris. We noted similar 6-year overall survival across donor types: matched
related donor, 47% (95% conﬁdence interval [CI], 39% to 54%); umbilical cord blood, 36% (95% CI, 28% to 44%);
matched unrelated donor, 54% (95% CI, 40% to 66%); and mismatched unrelated donor, 51% (95% CI, 28% to
70%) (P < .11). Survival differed based on conditioning intensity and age, with 6-year survival of 57% (95% CI,
47% to 65%), 39% (95% CI, 28% to 49%), 23% (95% CI, 6% to 47%), 47% (95% CI, 36% to 57%), and 28% (95% CI, 17%
to 41%) for MA age 18 to 39, MA age 40þ, or RIC ages 18 to 39, 40 to 56, and 57 to 74, respectively (P < .01).
Relapse was increased with RIC and lowest in younger patients receiving MA conditioning (hazard ratio, 1.0
versus 2.5 or above for all RIC age cohorts), P < .01. Transplantation-related mortality was similar across donor
types. In summary, our data support the use of alternative donors as a graft source with MA or RIC for patients
with acute myeloid leukemia when a sibling donor is unavailable.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT)
remains the only therapy that can provide extended disease-
free survival (DFS) for the majority of patients with acute
myeloid leukemia (AML) [1-3]However, post-transplantation
disease relapse remains amajor therapeutic challenge. Efforts
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ty for Blood and Marrow Transplantation.playing a role in post-HCT relapse risk continue, with
numerous reports documenting the role of cytogenetic risk,
conditioning intensity, age, and disease status in trans-
plantation outcomes for AML [4-11].
We analyzed the outcome of a large population of AML
patients who underwent transplantation at 2 large centers,
the University of Minnesota and Hôpital Saint Louis in Paris.
We report the impact of speciﬁc patient, disease, and trans-
plantation variables on clinical outcomes in cohorts receiving
similar myeloablative (MA) and reduced-intensity condi-
tioning (RIC) regimens. Our data highlight the interactions of
age, conditioning intensity, and donor source on post-
transplantation outcomes and support the use of alterna-
tive donors when a sibling donor is not available.
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Study Population
Between January 2000 and December 2010, 414 consecutive adult pa-
tients with AML in remission complete remission [CR 1, CR 2, or C3] received
MA or RIC allogeneic HCT from either an HLA-identical matched related
donor (MRD) (n ¼ 187), unrelated donor (URD) (n ¼ 76), or umbilical cord
blood (UCB) donor (n ¼ 151). Patients receiving more than 1 transplant for
AML, those with French American British subtype M3, and those in relapse
or with primary induction failure were excluded.
Risk Stratiﬁcation
Patients were risk stratiﬁed based on disease status at transplantation (CR
1, CR 2, or CR 3) and by cytogenetic risk. Cytogenetic classiﬁcationwas limited
by the differential availability of speciﬁc details between the 2 databases. The
Paris datawas available in ProMISe (Project Manager Internet Server) and the
European Group for Blood and Marrow Transplantation Web shared data
base, in the following format: normal or abnormal chromosomes, presence or
absence of complex karyotype, presence or absence of molecular markers
with partial reporting ofwhichmolecularmarker (NPM-1 [nucleophosmin 1],
FLT-3 [FMS-like tyroisube kinase-3], BCR-ABL [breakpoint cluster region-ABL1
fusion], WT-1 [Wilms Tumor 1], MLL [Mixed lineage leukemia with 11q23
abnormality, AML-ETO]) was present. The availability of this data was
confounded by the time period of the study since 2000. Complete cytogenetic
data were available for the majority of University of Minnesota cases and FLT-
3 or NMP-1molecular datawas available in more recent years. Merging these
2 data sets, we classiﬁed risk using cytogenetic and molecular risk data as
follows: standard risk included normal karyotype, favorable abnormalities
including t(8;21) or inversion 16, CEBPA mutation, or NPM-1 mutation in the
absence of FLT-3 ITD; poor risk included complex karyotype, monosomy 7,
monosomy 5, monosomal karyotype, BCR-ABL, FLT-3 ITD, MLL (11q23), or all
other known high-risk abnormalities; abnormal and uncertain signiﬁcance
included cases where an abnormality was documented without speciﬁcs or
an abnormality of uncertain clinical signiﬁcance was present (examples
include CBF (core binding factor) þ c-KIT (protooncogene encoding the
tyrosine kinase KIT) þWT-1 or NPM-1 þWT-1).
HLA Typing, Matching, and Donor Selection
HLA-identical MRD were primarily siblings based on family testing.
URDs were deﬁned as matched (8/8) if HLA-A, -C,-B, and-DRB1 were iden-
tical at the allele level [12]. Stem cells were harvested for sibling or URDs via
marrow harvest (n ¼ 74) or ﬁlgrastim-mobilized peripheral blood (n¼ 189).
UCB unit nucleated cell dose and matching have been described elsewhere
[13]; however, in brief they were required to have a minimum of 4/6 antigen
match between each cord and the recipient. In the absence of a sibling
donor, UCB was the graft choice of preference for the University of Minne-
sota based on research priorities, whereas Hôpital Saint-Louis utilized URDs
in this situation. Preparative regimens were classiﬁed as either MA or RIC by
established Center for International Blood and Marrow Transplant Research
functional deﬁnitions [14-16].
Treatment
Patients received either MA or RIC conditioning. MA conditioning from
Paris included 120 mg/kg cyclophosphamide (60 mg/kg, on each of 2
consecutive days) and busulfan (3.2 mg/kg i.v. daily on 4 consecutive days),
or 12 Gy total body irradiation (TBI) in a fractionated regimen. For the
University of Minnesota, the MA regimen for MRD and URD was cyclo-
phosphomide (60 mg/kg  day 6 and 5) plus TBI (165 cGy twice daily for
8 fractions on days 4 through 1). UCB MA conditioning consisted of
ﬂudarabine (25 mg/m2 daily on days 8 through 6), cyclophosphamide
(60 mg/kg i.v. daily on days 7 and 6), and TBI (165 cGy twice daily for 8
fractions on days 4 through 1). RIC at the Hôpital Saint-Louis consisted
predominantly of ﬂudarabine (30 mg/m2 i.v. daily from days 5
through 1), busulfan (3.2 mg/kg i.v. twice daily on days 4 and 3) plus
rabbit antithymocyte globulin (ATG; 5 mg/kg for siblings and 10 mg/kg for
URDs on days 2 and 1). The University of Minnesota RIC regimen con-
sisted of cyclophosphamide (50mg/kg on day6), ﬂudarabine (30 to 40mg/
m2 i.v. daily on days 6 through 2), and TBI (200 cGy on day 1) for all
donor sources. Equine ATG (15 mg/kg twice daily for 6 doses from day 6
through day4) in the setting of RIC was used for those URDs who had only
1 cycle of multiagent chemotherapy within 3 months or for related donors
with only 1 cycle of multiagent chemotherapy within 6 months before HCT.
Graft-versus-host disease (GVHD) prophylaxis included cyclosporine
(day3 throughþ100 to 180) plus mycophenolate mofetil (days3 toþ30)
(56%) or cyclosporine plus methotrexate (40%).
Supportive care was similar in both institutions. Patients were hospi-
talized in single rooms utilizing high efﬁciency air ﬁltration systems. Pa-
tients received prophylactic acyclovir for herpes simplex virus or
cytomegalovirus prophylaxis plus antibacterial prophylaxis until day þ21 orlonger if on prednisone for GVHD; fungal prophylaxis with either ﬂucona-
zole or voriconazole for 100 days; and pneumocystis juroveci prophylaxis
typically with trimethoprim sulfamethoxazole for 1 year.
Data Collection
All patients were treated on protocols approved by the institutional
review board of each hospital with prior informed consent for treatment
and data analysis.
Datawere prospectively collected. Data fromHôpital Saint-Louis in Paris
was retrieved through the European Group for Blood and Marrow Trans-
plantation and data from the University of Minnesota were prospectively
collected in the institutional blood and marrow transplantation database.
Data were merged for the combined analysis.
Statistical Analysis
The primary endpoint was overall survival (OS). Secondary endpoints
included hematopoietic recovery, occurrence of acute GVHD and chronic
GVHD, transplantation-related mortality (TRM), incidence of relapse, and
DFS. OSwas deﬁned as time to death from any cause and a 6-year time point
was used because of the availability of extended follow-up. Hematopoietic
recovery was deﬁned as time to absolute neutrophil count (ANC)  500
neutrophils/mL for 3 consecutive days. Incidence and grade of acute GVHD
(aGVHD) at day þ100 and absence or presence of chronic GVHD (cGVHD) at
2 years were recorded based on consensus criteria [17,18]. TRM was deﬁned
as any death in the ﬁrst 28 days after HCT or death after day 28 without
evidence of relapsed leukemia. TRM results are reported at 1 year to capture
later deaths due to transplantation-related toxicity. Relapse was deﬁned as
hematologic evidence of disease recurrence with those surviving without
relapse censored at the date of last contact. Relapse was reported at 2 years
as most post-transplantation relapses are evident within that time period.
DFSwas deﬁned as survival without death or relapse censoring at the date of
last contact.
Univariate probabilities of DFS and OS were calculated using the Kaplan-
Meier estimator with variance estimated by Greenwood’s formula [19].
Probabilities of aGVHD, cGVHD, TRM, and relapse were calculated using
cumulative incidence curves to accommodate competing risks [20]. Ninety-
ﬁve percent conﬁdence intervals (CI) for all probabilities and P values of
pair-wise comparisons were derived from point-wise estimates and calcu-
lated. Single variable comparisons were made using log-rank tests with
standard weights.
Multivariable regression models were ﬁt for each outcome: Cox
regression [21] for OS and DFS, and Fine and Gray [22] competing risks
regression for all other outcomes, reported as hazard ratios (HR). TRM was
analyzed with a competing risk of relapse, and relapse, GVHD, and he-
matopoietic recovery were analyzed with a competing risk of mortality. All
models were prespeciﬁed and included categorical factors for cytogenetic
(standard, poor, abnormal but unknown signiﬁcance), donor type (MRD,
UCB, matched URD,mismatched URD), disease status (CR1, CR2, or CR3), and
age and conditioning combinations (MA 18 to 39, MA 40 to 56, RIC 18 to 39,
RIC 40 to 56, and RIC 57 to 74) because of their association. Subgroup
analysis investigation showed no signiﬁcant association between donor
source and conditioning and, thus, was not included in ﬁnal modeling.
Treatment center had minimal inﬂuence; thus, was not included in the ﬁnal
models. SAS software (SAS Institute, Cary, NC) was used to perform statis-
tical analyses.
RESULTS
Patient Characteristics
Patient characteristics (Table 1) were similar across donor
types (MRD, UCB, URD) with respect to gender, Karnofsky
performance status, and age. MRD had fewer cases with
poor-risk cytogenetic/molecular proﬁle compared with UCB
or to matched and mismatched URD (38% versus 53%, 51%,
and 52%, respectively). There were many MRD treated in CR1
(78% versus 58% in UCB, 73% in matched URD, and 48% in
mismatched URD). UCB (64%) transplant recipients were
more likely to receive RIC compared with MRD (40%) and
compared with matched (25%) or mismatched URDs (10%).
Those receiving URD stem cell sources weremore likely to be
exposed to ATG in their conditioning compared with MRD
and UCB (45% to 48% matched and mismatched URD versus
11% MRD and 15% UCB). GVHD prophylaxis associated with
conditioning intensity, with a higher percentage of cyclo-
sporine/methotrexate in the MRD and URD cohorts.
Table 1
Patient Characteristics by Donor Type
MRD* UCB Matched URD Mismatched URD Total
No. of patients 187 151 55 21 414
Cytogenetic classiﬁcation
Poor 71 (38) 80 (53) 28 (51) 11 (52) 190 (46)
Standard 74 (40) 62 (41) 15 (27) 2 (10) 153 (37)
Abnormal of unknown signiﬁcance 42 (22) 9 (6) 12 (22) 8 (38) 71 (17)
Age
18-39 57 (30) 49 (32) 21 (38) 13 (62) 140 (34)
40-56 91 (49) 62 (41) 24 (44) 7 (33) 184 (44)
57-74 39 (21) 40 (26) 10 (18) 1 (5) 90 (22)
Disease status at HCT
CR1 145 (78) 88 (58) 40 (73) 10 (48) 283 (68)
CR2 or CR3 42 (22) 63 (42) 15 (27) 11 (52) 131 (32)
Gender
Female 86 (46) 73 (48) 25 (45) 7 (33) 191 (46)
Male 101 (54) 78 (52) 30 (55) 14 (67) 223 (54)
Conditioning
MA 112 (60) 55 (36) 36 (65) 19 (90) 222 (54)
RIC 75 (40) 96 (64) 19 (35) 2 (10) 192 (46)
Graft source
Cord blood 0 (0) 151 (100) 0 (0) 0 (0) 151 (36)
Marrow 45 (24) 0 (0) 20 (36) 9 (43) 74 (18)
PBSC 142 (76) 0 (0) 35 (64) 12 (57) 189 (46)
GVHD prophylaxis
CSA/MMF 71 (38) 144 (95) 16 (29) 2 (10) 233 (56)
CSA/MTX 110 (59) 0 (0) 35 (64) 19 (90) 164 (40)
Other 6 (3) 7 (5) 4 (7) 0 (0) 17 (4)
ATG use
Yes 20 (11) 22 (15) 25 (45) 10 (48) 77 (19)
No 167 (89) 129 (85) 30 (55) 11 (52) 337 (81)
CMV
Rþ 116 (62) 88 (58) 25 (45) 15 (71) 244 (59)
R/D 50 (27) 63 (42) 20 (36) 3 (14) 136 (33)
R/Dþ 21 (11) 0 (0) 10 (18) 3 (14) 34 (8)
Karnofsky score
80 49 (26) 27 (18) 11 (20) 8 (38) 95 (23)
90-100 134 (72) 121 (80) 44 (80) 13 (62) 312 (75)
Unknown 4 (2) 3 (2) 0 (0) 0 (0) 7 (2)
Years from diagnosis to HCT
Median .4 .5 .5 1.2 .5
Range .2-7.8 .1-7.8 .4-3.3 .3-13.7 .1-13.7
PBSC indicates peripheral blood stem cells; CSA, cyclosporine; MMF, mycophenylate mofetil; MTX, methotrexate; ATG, antithymocyte globulin; CMV, cyto-
megalovirus; R, recipient; D, donor.
Data presented are n (%) unless otherwise indicated.
* Includes 8 nonsibling related donors.
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The median time to engraftment of ANC was 16 days with
96% recovering by day þ50. Twelve events of primary graft
failure were noted; 10 in the UCB group. In multivariate
analysis, the only factors predictive of time to neutrophil
recovery were conditioning intensity and donor type, with
quicker ANC recovery in the RIC groups (age 18 to 39: HR, .5;
95% CI, .3 to .9; age 40 to 56: HR, .5; 95% CI, .3 to .6; and age 57
to 74: HR, .6; 95% CI, .4 to .8; P< .01) and slower, less frequent
recovery in UCB donors (HR, 2.8; 95% CI, 2.1 to 3.6) P < .01.
Survival
After a median follow-up of 5.2 years, 184 patients sur-
vived. The 6-year probability of survival was 44% (95% CI, 38%
to 49%).
We observed similar 6-year OS across donor types: MRD,
47% (95% CI, 39% to 54%); UCB, 36% (95% CI, 28% to 44%);
matched URD, 54% (95% CI, 40% to 66%); and mismatched
URD, 51% (95% CI, 28% to70%) (P < .11) (Table 2, Figure 1). We
observed a nonsigniﬁcant ﬁnding of somewhat poorer sur-
vival in patients undergoing RIC UCB at 28% (95% CI, 19% to
38%) compared with RIC MRD of 46% (95% CI, 33% to 58%) or
matched URD at 52% (95% CI, 29% to 72%) (P < .23). However,
the patients undergoing RIC UCB were more often in CR2 orCR3 (39% versus 28% in MRD and 21% in matched URD) and a
greater proportion had poor-risk cytogenetics (55% versus
44% in MRD).
Six-year OS differed in signiﬁcance based on age and
conditioning intensity, as follows: MA age 18 to 39, 57% (95%
CI, 47% to 65%); MA age 40þ, 39% (95% CI, 28% to 49%), RIC
age 18 to 39, 23% (95% CI, 6% to 47%); RIC age 40 to 56, 47%
(95% CI, 36% to 57%); and RIC age 57 to 74, 28% (95% CI, 17% to
41%) (P < .01) (Table 2, Figure 2). The interaction of age and
conditioning remained important in multivariate analysis as
younger patients (age 18 to 39) undergoing MA had superior
survival compared with a small cohort of similar aged pa-
tients undergoing RIC HCT (HR, 2.3; 95% CI, 1.1 to 4.6; P< .01)
(Table 3). This small cohort (RIC, age 18 to 39; n ¼ 13), in
comparison to the MA (age 18 to 39) cohort, had more with
Karnofsky performance status  80 (46% versus 20%),
advanced remission status CR2 or CR3 (46% versus 34%), and
poor-risk cytogenetics (54% versus 43%). Notably, TRM and
relapse risks were higher in this group and account for their
poor survival.
The majority of deaths were due to disease recurrence
(n ¼ 119, 52%) with GVHD (n ¼ 32, 14%), infection (n ¼ 28,
12%), other miscellaneous HCT-related complications
(n ¼ 46, 20%) (septic shock, organ failure, graft failure,
Table 2
Univariate Analysis of HCT Outcomes
N (%) Six-year OS
(95% CI)
Six-year DFS
(95% CI)
Two-year Relapse
(95% CI)
One-year TRM
(95% CI)
Total 414 (100) 44% (38-49) 41% (36-46) 29% (24-34) 20% (16-24)
Cytogenetic classiﬁcation P < .07 P < .02 P < .04 P < .33
Poor 190 (46) 40% (33-47) 35% (28-42) 34% (27-41) 23% (17-28)
Standard 153 (37) 46% (37-54) 44% (35-52) 26% (18-33) 18% (12-24)
Abnormal of unknown signiﬁcance 71 (17) 50% (37-62) 50% (38-62) 24% (14-34) 18% (9-27)
Donor type/HLA matching P < .11 P < .11 P < .05 P < .53
MRD 187 (45) 47% (39-54) 44% (37-52) 26% (19-32) 20% (14-25)
UCB 151 (36) 36% (28-44) 34% (27-42) 36% (28-45) 20% (14-26)
URD matched 55 (13) 54% (40-66) 50% (36-63) 20% (9-31) 25% (14-37)
URD mismatched 21 (5) 51% (28-70) 39% (18-60) 33% (13-53) 14% (4-29)
Disease status at HCT P < .09 P < .10 P < .04 P < .80
CR1 283 (68) 46% (40-52) 44% (38-50) 26% (21-31) 20% (15-25)
CR2 or CR3 131 (32) 38% (29-46) 35% (26-43) 36% (27-45) 21% (14-27)
Gender P < .25 P < .17 P < .57 P < .84
Female 191 (46) 49% (42-57) 47% (40-54) 28% (21-34) 21% (15-27)
Male 223 (54) 39% (32-46) 36% (29-43) 30% (24-37) 20% (14-25)
Conditioning/age P < .01 P < .01 P < .01 P < .10
MA/18-39 127 (31) 57% (47-65) 55% (45-63) 18% (11-25) 18% (11-25)
MA/40-56 95 (23) 39% (28-49) 39% (29-49) 25% (16-34) 31% (21-40)
RIC/18-39 13 (3) 23% (6-47) 12% (1-38) 38% (12-64) 31% (10-55)
RIC/40-56 90 (22) 47% (36-57) 38% (27-48) 39% (28-50) 16% (8-23)
RIC/57-74 89 (22) 28% (17-41) 28% (16-40) 38% (28-49) 16% (8-23)
P values in bold indicate statistical signiﬁcance.
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malignancy, graft failure), and unknown (n ¼ 5, 2%) ac-
counting for the remainder.
DFS was 41% (95% CI, 36% to 46%); however, as the ma-
jority of relapsing patients died, DFS was similar to OS.Relapse and TRM
The overall incidence of relapse at 2 years was 29% (95%
CI, 24% to 34%). Relapse was more frequent in those with
higher risk disease as deﬁned by cytogenetics or remission
status at transplantation. Two-year relapse for those with
poor-risk cytogenetic/molecular proﬁles was 34% (95% CI,
27% to 41%) versus 26% for those with standard risk (95% CI,
18% to 33%) or 24% for those with abnormal/unknown sig-
niﬁcance (95% CI, 14% to 34%) (P < .04). For those who un-
derwent transplantation in CR2 or CR3, relapse was
increased at 36% (95% CI, 27% to 45%) versus 26% (95% CI, 21%
to 31%) for those in CR1 (P < .04). Lastly, conditioning in-
tensity inﬂuenced relapse, with those receiving RIC showing
an incidence of 38% to 39% across all age cohorts compared
with 18% and 25% in the MA age 18 to 39 and 40 to 56 age
groups, respectively (P < .01).Figure 1. Survival based on donor source.In univariate analysis, relapse was slightly increased in
those receiving UCB transplants at 36% (95% CI, 28% to 45%)
and mismatched URD at 33% (95% CI, 13% to 53%) compared
withmatched URD at 20% (95% CI, 9% to 31%) andMRD at 26%
(95% CI, 19% to 32%) (P < .05) (Figure 3A). However, UCB re-
cipients were more likely to receive RIC, and in multivariate
analysis, conditioning/age remained signiﬁcantly associated
with relapse (P < .01) but donor type did not (P < .34)
(Table 3). Subgroup analysis showed that the combination of
UCB and RIC had particularly high relapse of 46% (95% CI, 35%
to 57%) compared with 20% (95% CI, 9% to 31%) in those
receiving MA UCB (P < .01). As noted, these RIC UCB re-
cipients had more advanced disease and more poor-risk cy-
togenetics, and in multivariate analysis of relapse,
signiﬁcantly higher relapse rates were observed across all
age cohorts of RIC HCT (P < .001) (Table 3).
TRM at 1 year was 20% (95% CI, 16% to 24%). We observed
no signiﬁcant differences based on remission status, donor
type (Figure 3B), cytogenetic/molecular risk group, or
gender. Compared with the younger MA group, TRM was
highest in older MA patients, ages 40 to 56, compared with
the younger MA group (HR, 1.8; 95% CI, 1 to 3) and was also
higher in the youngest RIC cohort, ages 18 to 39, as explainedFigure 2. Survival based on age and conditioning.
Figure 3. (A) Inﬂuence of donor source on relapse. (B) Inﬂuence of donor
source on TRM.
Table 3
Multivariate Analysis
Risk Factor Six-year OS Two-year Relapse One-year TRM
HR 95% CI HR 95% CI HR 95% CI
Cytogenetic classiﬁcation P < .11 P < .10 P < .44
Standard 1.0 - 1.0 - 1.0 -
Abnormal of unknown signiﬁcance .9 .6-1.4 1.3 .7-2.5 .8 .4-1.5
Poor 1.3 1.0-1.8 1.6 1.0-2.4 1.2 .7-1.9
Donor type P < .28 P < .34 P < .40
MRD 1.0 - 1.0 - 1.0 -
UCB 1.3 1.0-1.8 1.3 .9-1.9 1.4 .8-2.3
URD matched 1.0 .6-1.6 .8 .4-1.5 1.4 .8-2.7
URD mismatched 1.0 .5-1.9 1.5 .6-3.4 .7 .2-2.4
Gender P < .60 P < .71 P < .98
Female 1.0 - 1.0 - 1.0 -
Male 1.1 .8-1.4 1.1 .7-1.5 1.0 .6-1.5
Disease status P < .05 P < .06 P < .94
CR1 1.0 - 1.0 - 1.0 -
CR2 or CR3 1.3 1.0-1.8 1.5 1.0-2.2 1.0 .6-1.6
Conditioning/age P < .01 P < .01 P < .04
MA/18-39 years 1.0 - 1.0 - 1.0 -
MA/40-56 1.9 1.3-2.8 1.6 .9-2.9 1.8 1.0-3.0
RIC/18-39 2.3 1.1-4.6 2.6 1.0-7.0 1.5 .5-4.3
RIC/40-56 1.3 .9-2.0 2.6 1.5-4.5 .6 .3-1.3
RIC/57-74 1.7 1.2-2.5 2.5 1.4-4.3 .9 .5-1.6
HR and P values in bold indicate statistical signiﬁcance.
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(HR, 1.5; 95% CI, .5 to 4.3), P < .04.
aGHVD and cGVHD
The incidence of day þ100 aGVHD grade II to IV for the
entire cohort was 62% (95% CI, 56% to 67%) with only 16%
(95% CI, 12% to 19%) severe grade III and IV aGVHD. Severe
aGVHD was lowest in MRD at 9% (95% CI, 5% to 13%)
compared with URD at 15% (95% CI, 5% to 24%), UCB at 24%
(95% CI,17 to 31%), andmismatched URD at 24% (95% CI, 6% to
42%) P < .01. In multivariate analysis, a higher risk of severe
aGHVD was observed in those receiving an UCB graft source
(HR, 3.2; 95% CI, 1.6 to 6.2) or mismatched URD (HR, 2.6; 95%
CI, .9 to 7.8) (P < .01) and in males (HR, 1.7; 95% CI, 1 to 2.7,
P < .05).
The overall incidence of cGVHD at 2 years was 34% (95%
CI, 29% to 39%). In multivariate analysis, risk of cGVHD was
higher in males (HR, 1.8; 95% CI, 1.3 to 2.6) (P < .01) and HCTs
during CR2/CR3 (HR,1.5; 95% CI,1.0 to 2.1; P< .03). Therewas
no signiﬁcant inﬂuence of donor type, age, or conditioning
intensity on the incidence of cGVHD.
DISCUSSION
We investigated patient, disease, and transplantation
factors affecting survival, relapse, and TRM risk in a well-
characterized population of 414 adult AML patients
receiving consistent MA and RIC HCT regimens. Our analyses
revealed similar outcomes for transplantations across donor
sources and with MA or RIC regimens. These ﬁndings build
upon earlier reports in the older RIC setting [23] and provide
solid support for use of alternative donors when a sibling
donor is unavailable. Our data also highlight the interaction
of conditioning intensity and age, the impact of remission
status at transplantation and cytogenetic risk, and the
increased relapse risks in those receiving RIC conditioning.
Thus, our data support the use of MA conditioning to limit
relapse risk when feasible.
Of notable importance, our study evaluates a heteroge-
neous cohort of patients treated with 3 different donorsources across both MA and RIC conditioning approaches. As
may occur in any retrospective review, the groups are not
evenly balanced with respect to disease or transplantation
characteristics, which could affect outcome. Extensive subset
analysis when patient numbers within subsets are small can
potentially lead to incorrect conclusions. Although we
E.D. Warlick et al. / Biol Blood Marrow Transplant 21 (2015) 357e363362analyze important subsets in our manuscript, we attempted
to minimize overgeneralizations based upon statistically
insigniﬁcant analyses. Overall, we demonstrated that OS was
similar across donor types and that high-risk disease fea-
tures, including poor-risk cytogenetics, advanced disease
stage (CR2 or CR3), and RIC contributed more to risk of
relapse than did donor source. Although we observed a trend
to inferior OS in those patients undergoing RIC, paired in-
teractions of donor source and conditioning intensity were
not statistically signiﬁcant, supporting our main conclusions.
Prior comparisons of HCT using alternative donor sources
have had mixed results. Some reports have suggested
increased TRM using mismatched URDs and UCB donor
sources and, consequently, lower survival [24,25]. Others
have reported improved outcomes for older patients with
sibling donors versus URDs [26] yet comparable results with
URDs and UCB [27]. We recently reported a collaborative
analysis investigating donor source in an older (age 50þ)
cohort of AML patients, all receiving RIC, and revealed similar
outcomes using MRDs, URDs, and UCB donors [23]. The
current study, a larger group of adults with AML receiving
RIC and MA conditioning at our 2 centers, highlights similar
survival, DFS, relapse, and TRM across donor sources with
either conditioning intensity. Our study did not include
haploidentical donor sources. However, as this alternative
donor options is studied further and is currently the basis of
an ongoing Blood and Marrow Transplant Clinical Trials
Network randomized trial using RIC (protocol 1101), forth-
coming data will allow for comparisons including this
alternative donor source.
Clear data on the value of greater conditioning regimen
intensity for AML andMDS are still lacking, though the use of
RIC has increased to offer allogeneic HCT to older patients.
Many retrospective studies have highlighted lower risks of
TRM offset by increased rates of relapse in RIC with similar
OS [28-31]. More recent studies note similar outcomes for
those in complete remission [32,33]. This ongoing condi-
tioning intensity debate prompted a national randomized
trial within the Blood and Marrow Transplant Clinical Trials
Network 0901 to prospectively answer this question.
Although closed to accrual, future reports of their datawill be
helpful in answering this question. In the interim, our data
strongly suggest lower relapse in patients receiving MA
conditioning.
Rates of advanced aGVHDwere highest in those receiving
UCB or mismatched URD stem cell sources, but they were in
line with other published reports [27]. Our UCB and mis-
matched URD cohorts included a higher proportion of those
with advanced disease status (CR2 and CR3) and poor-risk
cytogenetics and, thus, they may have been more heavily
pretreated entering transplantation, thereby increasing their
risk of severe aGVHD. cGVHD rates were associated with
more advanced disease.
Our data highlight long follow-up of a sizeable population
treated uniformly in 2 experienced centers and support the
use of alternative donors as a graft source for patients with
nonfavorable risk AML when a sibling donor is unavailable.
Clinically suitable patients should be considered for MA
conditioning to reduce relapse risk.
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